Across TCGA pan-cancer cohorts, C6orf136 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C6orf136 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher C6orf136 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C6orf136 expression acts as an unfavorable survival marker.

OV, LUSC, and SCLC are the cancer types where C6orf136 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.215	0.541	.027	18	view →
LUSC	OS	Median	III,IV	0.140	0.664	.016	12	view →
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
BLCA	DFS	Median	All	0.078	0.594	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: C6orf136 tumor-vs-normal RNA expression · all C6orf136 data types